Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.47 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281473 | 1.00 | SCN9A (0.47) | SCN9AP4HBGAATSHRALDH1A1 | |
| SCHEMBL15312952 | 0.94 | SCN9A (0.41) | SCN9AP4HBGAATSHRALDH1A1 | |
| SCHEMBL282071 | 0.89 | SCN9A (0.40) | SCN9AP4HBGAATSHRALDH1A1 | |
| SCHEMBL281655 | 0.86 | SCN9A (0.36) | SCN9AP4HBGAAALDH1A1MAPT | |
| SCHEMBL281653 | 0.86 | SCN9A (0.36) | SCN9AGAAALDH1A1MAPT | |
| SCHEMBL281490 | 0.85 | SCN9A (0.38) | SCN9AP4HBGAATSHRALDH1A1 | |
| SCHEMBL281082 | 0.85 | SCN9A (0.47) | SCN9AGAATSHRALDH1A1MEN1 | |
| SCHEMBL281702 | 0.84 | SCN9A (0.46) | SCN9AP4HBGAATSHRALDH1A1 | |
| SCHEMBL1612150 | 0.84 | SCN9A (0.56) | SCN9AALDH1A1MEN1KMT2A | |
| SCHEMBL3007855 | 0.82 | SCN9A (0.52) | SCN9AGAATSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838902-B1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| EP-2838902-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-02-25 | — | — | EP | disclosed |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013154712-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-10-17 | — | — | WO | disclosed |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013154712-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-10-17 | — | — | WO | disclosed |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | SCN9A 51/4885P4HB 3458/4885GAA 4090/4885 |
| US-20130274483-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | SCN9A 51/4885P4HB 3458/4885GAA 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.